{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:39:38Z","timestamp":1790156378713,"version":"4.0.1"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Chronic Bacterial Prostatitis (CBP) is inflammation of the prostate caused by bacterial infection. An estimated 8.2% of men have prostatitis, most commonly under the age of 50. Antibiotics often fail to treat CBP due to presence of bacterial biofilms and rising antibiotic resistance of pathogenic bacterial strains. The multidrug resistant (MDR) bacterial strains often implicated in cases of CBP include Extended Spectrum Beta Lactam resistant <jats:italic>Escherichia coli<\/jats:italic>, Vancomycin resistant Enterococci, Gram-positive bacterial strains like Staphylococci and Streptococci, Enterobacteriaceae like <jats:italic>Klebsiella<\/jats:italic> and <jats:italic>Proteus<\/jats:italic>, and <jats:italic>Pseudomonas aeruginosa<\/jats:italic>. CBP patients experience significant deterioration in quality of life, with impact on mental health comparable with patients of diabetes mellitus and chronic heart failure, leading patients to explore alternatives like phage therapy.<\/jats:p><jats:p><jats:bold>Case presentation:<\/jats:bold> We present the case of a patient diagnosed with and exhibiting typical symptoms of CBP. Tests of the prostatic and seminal fluids identified <jats:italic>E. coli<\/jats:italic> as the causative pathogen. The patient did not experience favourable long-term treatment outcomes despite repeated antibiotic courses administered over 5\u00a0years. This led him to seek phage therapy for treatment of his condition.<\/jats:p><jats:p><jats:bold>Methods and outcome:<\/jats:bold> The cultured strain of <jats:italic>E. coli<\/jats:italic> was tested against bacteriophage preparations developed by the Eliava Institute, Georgia. Preparations showing lytic activity against the strain were used for the patient\u2019s treatment at the Eliava Phage Therapy Center (EPTC). The patient underwent two courses of treatment with the EPTC. The first treatment course resulted in significant symptomatic improvement, followed by complete resolution of symptoms post the second course of phage therapy. Samples tested during treatment showed declining bacterial growth, corresponding with symptomatic improvement. Post-treatment cultures had no growth of pathogenic bacteria.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> This case illustrates the efficacy of bacteriophages in treating CBP, a condition that is often resistant to antibiotic therapies. Antibiotics such as ofloxacin, Fosfomycin, trimethoprim, nitrofurantoin and ceftriaxone were administered in multiple courses over 5\u00a0years, but the infection recurred after each course. After two courses of phage therapy, the patient experienced long-term symptom resolution and substantial reduction in bacterial load. Increasing numbers of such cases globally warrant further research into the potential for bacteriophages for treating MDR and chronic infections.<\/jats:p>","DOI":"10.3389\/fphar.2023.1243824","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T07:36:29Z","timestamp":1695108989000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Case report: Successful treatment of recurrent E. coli infection with bacteriophage therapy for patient suffering from chronic bacterial prostatitis"],"prefix":"10.3389","volume":"14","author":[{"given":"Apurva Virmani","family":"Johri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Johri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Hoyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"Nadareishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levan","family":"Pipia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dea","family":"Nizharadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4161\/bact.1.2.15845","article-title":"Phage treatment of human infections","volume":"1","author":"Abedon","year":"2011","journal-title":"Bacteriophage"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11786337211033870","DOI":"10.1177\/11786337211033870","article-title":"COVID-19 and antimicrobial resistance: A review","volume":"14","author":"Adebisi","year":"2021","journal-title":"Infect. Dis. Aukl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jama.2010.1913","article-title":"Management of chronic prostatitis\/chronic pelvic pain syndrome: A systematic review and network meta-analysis","volume":"305","author":"Anothaisintawee","year":"2011","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"B5","unstructured":"STAMP protocol approved for phage therapy in Australia2022"},{"key":"B7","first-page":"1802","article-title":"Chronic bacterial prostatitis and chronic pelvic pain syndrome","volume":"2015","author":"Bowen","year":"2015","journal-title":"BMJ Clin. Evid."},{"key":"B8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/00365590600748247","article-title":"Value of semen culture in the diagnosis of chronic bacterial prostatitis: A simplified method","volume":"40","author":"Budia","year":"2006","journal-title":"Scand. J. Urology Nephrol."},{"key":"B9","first-page":"267","article-title":"Phage therapy: Past history and future prospects","volume":"47","author":"Carlton","year":"1999","journal-title":"Archivum Immunol. Ther. Exp."},{"key":"B10","volume-title":"COVID-19: U.S. Impact on antimicrobial resistance","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2174\/156720181303160520193946","article-title":"Bacteriophages as therapeutic and prophylactic means: Summary of the soviet and post soviet experiences","volume":"13","author":"Chanishvili","year":"2016","journal-title":"Curr. Drug Deliv."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e799","DOI":"10.1371\/journal.pone.0000799","article-title":"Phage-antibiotic synergy (PAS): \u03b2-Lactam and quinolone antibiotics stimulate virulent phage growth","volume":"2","author":"Comeau","year":"2007","journal-title":"PLOS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.284.5418.1318","article-title":"Bacterial biofilms: A common cause of persistent infections","volume":"284","author":"Costerton","year":"1999","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.21775\/cimb.040.081","article-title":"Phage therapy: The pharmacology of antibacterial viruses","volume":"40","author":"Danis-Wlodarczyk","year":"2021","journal-title":"Curr. Issues Mol. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.mib.2013.06.013","article-title":"Bacterial biofilm development as a multicellular adaptation: Antibiotic resistance and new therapeutic strategies","volume":"16","author":"de la Fuente-N\u00fa\u00f1ez","year":"2013","journal-title":"Curr. Opin. Microbiol."},{"key":"B6","unstructured":"2023"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3389\/fmicb.2018.01434","article-title":"Phage therapy in prostatitis: Recent prospects","volume":"9","author":"G\u00f3rski","year":"2018","journal-title":"Front. Microbiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/B978-0-12-394438-2.00002-5","article-title":"Phage as a modulator of immune responses: Practical implications for phage therapy","volume":"83","author":"G\u00f3rski","year":"2012","journal-title":"Adv. Virus Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"104048","DOI":"10.1016\/j.micpath.2020.104048","article-title":"Therapeutic applications of lytic phages in human medicine","volume":"142","author":"Guo","year":"2020","journal-title":"Microb. Pathog."},{"key":"B19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev-med-080219-122208","article-title":"Phage therapy for antibiotic-resistant bacterial infections","volume":"73","author":"Hatfull","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1201\/9781003099277-57","article-title":"Phage therapy: Bacteriophages as natural, self-replicating antimicrobials","volume-title":"Practical handbook of Microbiology","author":"Hoyle","year":"2021"},{"key":"B21","doi-asserted-by":"publisher","first-page":"692614","DOI":"10.3389\/fphar.2021.692614","article-title":"Case report: Chronic bacterial prostatitis treated with phage therapy after multiple failed antibiotic treatments","volume":"12","author":"Johri","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/v5030806","article-title":"Understanding bacteriophage specificity in natural microbial communities","volume":"5","author":"Koskella","year":"2013","journal-title":"Viruses"},{"key":"B23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ijantimicag.2007.08.028","article-title":"Epidemiology of prostatitis","volume":"31","author":"Krieger","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1001\/jama.282.3.236","article-title":"NIH consensus definition and classification of prostatitis","volume":"282","author":"Krieger","year":"1999","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ijid.2016.11.121","article-title":"Bacteriophages against multidrug resistant bacterial infections","volume":"53","author":"Kutateladze","year":"2016","journal-title":"Int. J. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/138920110790725401","article-title":"Phage therapy in clinical practice: Treatment of human infections","volume":"11","author":"Kutter","year":"2010","journal-title":"Curr. Pharm. Biotechnol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/s1473-3099(20)30330-3","article-title":"Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: A randomised, placebo-controlled, double-blind clinical trial","volume":"21","author":"Leitner","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1574-695X.2010.00723.x","article-title":"The perspectives of the application of phage therapy in chronic bacterial prostatitis","volume":"60","author":"Letkiewicz","year":"2010","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4161\/bact.1.2.14590","article-title":"Pros and cons of phage therapy","volume":"1","author":"Loc-Carrillo","year":"2011","journal-title":"Bacteriophage"},{"key":"B30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s43088-021-00141-8","article-title":"Phage therapy as a revolutionary medicine against Gram-positive bacterial infections","volume":"10","author":"Loganathan","year":"2021","journal-title":"Beni-Suef Univ. J. Basic Appl. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/aja.2009.5","article-title":"Semen analysis in chronic bacterial prostatitis: Diagnostic and therapeutic implications","volume":"11","author":"Magri","year":"2009","journal-title":"Asian J. Androl."},{"key":"B32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/s0966-842x(00)01913-2","article-title":"Mechanisms of biofilm resistance to antimicrobial agents","volume":"9","author":"Mah","year":"2001","journal-title":"Trends Microbiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3389\/fmicb.2020.01434","article-title":"Secondary bacterial infections during pulmonary viral disease: Phage therapeutics as alternatives to antibiotics?","volume":"11","author":"Manohar","year":"2020","journal-title":"Front. Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/idr14040067","article-title":"Oral Fosfomycin formulation in bacterial prostatitis: New role for an old molecule \u2013 brief literature review and clinical considerations","volume":"14","author":"Marino","year":"2022","journal-title":"Infect. Dis. Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1080\/14656566.2022.2077101","article-title":"Pharmacotherapeutic interventions for the treatment of bacterial prostatitis","volume":"23","author":"Marquez-Algaba","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1574-695x.2010.00659.x","article-title":"Biofilms in chronic bacterial prostatitis (NIH-II) and in prostatic calcifications","volume":"59","author":"Mazzoli","year":"2010","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1525-1497.2001.01223.x","article-title":"Quality of life is impaired in men with chronic prostatitis: The chronic prostatitis collaborative research network","volume":"16","author":"McNaughton Collins","year":"2001","journal-title":"J. General Intern. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"144","DOI":"10.37201\/req\/099.2022","article-title":"Microbial etiology of bacterial chronic prostatitis: Systematic review","volume":"36","author":"Mendoza-Rodr\u00edguez","year":"2023","journal-title":"Rev. Espa\u00f1ola Quimioter."},{"key":"B39","unstructured":"MeyrierA.\n            FeketeT.\n          Chronic bacterial prostatitis2023"},{"key":"B40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/IDR.S234353","article-title":"How phages overcome the challenges of drug resistant bacteria in clinical infections","volume":"13","author":"Moghadam","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"B42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/B978-1-4160-6911-9.00011-6","article-title":"Inflammatory and pain conditions of the male genitourinary tract: Prostatitis and related conditions, orchitis, and epididymitis","volume-title":"Campbell-Walsh-Wein Urology","author":"Nickel","year":"2012"},{"key":"B41","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/01.ju.0000082252.49374.e9","article-title":"Leukocytes and bacteria in men with chronic prostatitis\/chronic pelvic pain syndrome compared to asymptomatic controls","volume":"170","author":"Nickel","year":"2003","journal-title":"J. Urology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0022-5347(06)00498-8","article-title":"How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis\/chronic pelvic pain syndrome?","volume":"176","author":"Nickel","year":"2006","journal-title":"J. Urology"},{"key":"B44","volume-title":"Tackling drug resistant infections globally: Final report and recommendations","author":"O\u2019Neill","year":"2016"},{"key":"B45","article-title":"Antimicrobial resistance, fueled by the COVID-19 pandemic","volume-title":"Policy Brief November 2021","year":"2022"},{"key":"B46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.mib.2017.09.004","article-title":"Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections","volume":"39","author":"Pires","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/v10020064","article-title":"The magistral phage","volume":"10","author":"Pirnay","year":"2018","journal-title":"Viruses"},{"key":"B48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0090-4295(02)02381-6","article-title":"Inflammation and anti-inflammatory therapy in chronic prostatitis","volume":"60","author":"Pontari","year":"2002","journal-title":"Adult Urol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.juro.2007.01.128","article-title":"Prostatitis","volume":"177","author":"Pontari","year":"2007","journal-title":"J. Urology"},{"key":"B50","unstructured":"PontariM.\n          Chronic prostatitis and chronic pelvic pain syndrome2022"},{"key":"B51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/s0022-5347(17)54976-9","article-title":"Prevalence and significance of prostatic inflammation","volume":"125","author":"Schaeffer","year":"1981","journal-title":"J. Urology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ijantimicag.2007.08.028","article-title":"Prostatitis: Diagnosis and treatment","volume":"82","author":"Sharp","year":"2010","journal-title":"Am. Fam. Physician"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1189081","DOI":"10.3389\/fcimb.2023.1189081","article-title":"Is type III prostatitis also associated with bacterial infection?","volume":"13","author":"Song","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11934-020-00978-z","article-title":"Management of chronic bacterial prostatitis","volume":"21","author":"Su","year":"2020","journal-title":"Curr. Urol. Rep."},{"key":"B55","doi-asserted-by":"publisher","first-page":"11931","DOI":"10.3390\/ijerph191911931","article-title":"Antibiotic resistance during COVID-19: A systematic review","volume":"19","author":"Sulayyim","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B56","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1001\/jama.2019.0510","article-title":"FDA approves bacteriophage trial","volume":"321","author":"Voelker","year":"2019","journal-title":"JAMA"},{"key":"B57","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/QCO.0000000000000024","article-title":"Urinary tract infections and bacterial prostatitis in men","volume":"27","author":"Wagenlehner","year":"2014","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B58","volume-title":"Record number of countries contribute data revealing disturbing rates of antimicrobial resistance","year":"2020"},{"key":"B59","volume-title":"WHO publishes list of bacteria for which new antibiotics are urgently needed","year":"2017"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/s0022-5347(17)31662-2","article-title":"Prostatic fluid inflammation in prostatitis","volume":"152","author":"Wright","year":"1994","journal-title":"J. Urology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3389\/fphar.2020.00504","article-title":"Pharmacological interventions for bacterial prostatitis","volume":"11","author":"Xiong","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/aja.2012.40","article-title":"Prostatic calculi influence the antimicrobial efficacy in men with chronic bacterial prostatitis","volume":"14","author":"Zhao","year":"2012","journal-title":"Asian J. Androl."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1243824\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T07:36:37Z","timestamp":1695108997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1243824\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":62,"alternative-id":["10.3389\/fphar.2023.1243824"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1243824","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"article-number":"1243824"}}